QNTM Stock Analysis: Buy, Sell, or Hold?
QNTM - Quantum Biopharma Ltd. Class B Subordinate Voting Shares
$3.20
-0.09 (-2.74%)
âŧ
5d:
+8.47%
30d:
-8.05%
90d:
-20.0%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When QNTM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: QNTM is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: QNTM is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: QNTM is currently trading at $3.20, which is considered fair relative to its 30-day fair value range of $3.08 to $3.52.
Technical Outlook: Technically, QNTM is in a downtrend. Immediate support is located at $2.91, while resistance sits at $3.74.
Market Sentiment: QNTM scores 27/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.61 (+294.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, QNTM is in a downtrend. Immediate support is located at $2.91, while resistance sits at $3.74.
Market Sentiment: QNTM scores 27/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.61 (+294.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.08 -
$3.52
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (27/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 294.0% below Wall St target ($12.61)
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.08 -
$3.52
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.91
Resistance Level
$3.74
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Wall Street Target
$12.61
(+294.0%)
Share & Embed Analysis
Last updated: September 13, 2026 2:35 AM ET
Data refreshes hourly during market hours. Next update: 3:35 AM
Data refreshes hourly during market hours. Next update: 3:35 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is QNTM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 55 HOLD |